BR0309747A - Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial - Google Patents

Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial

Info

Publication number
BR0309747A
BR0309747A BR0309747-1A BR0309747A BR0309747A BR 0309747 A BR0309747 A BR 0309747A BR 0309747 A BR0309747 A BR 0309747A BR 0309747 A BR0309747 A BR 0309747A
Authority
BR
Brazil
Prior art keywords
treatment
vascular
growth factor
mediated
endothelial
Prior art date
Application number
BR0309747-1A
Other languages
English (en)
Inventor
David P Bingaman
Michael A Kapin
Daniel A Gamache
Gustav Graff
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0309747A publication Critical patent/BR0309747A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE DISTúRBIOS VASCULARES MEDIADOS PELO FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL". A presente invenção refere-se ao uso de amfenac e derivados incluindo o nepafenac, para o tratamento dos distúrbios vasculares mediados pelo fator de crescimento vascular endotelial.
BR0309747-1A 2002-05-03 2003-04-16 Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial BR0309747A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37742902P 2002-05-03 2002-05-03
PCT/US2003/011769 WO2003092669A2 (en) 2002-05-03 2003-04-16 Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac

Publications (1)

Publication Number Publication Date
BR0309747A true BR0309747A (pt) 2005-04-26

Family

ID=29401494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309747-1A BR0309747A (pt) 2002-05-03 2003-04-16 Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial

Country Status (11)

Country Link
US (2) US20050143468A1 (pt)
EP (1) EP1507522A2 (pt)
JP (1) JP2005525408A (pt)
KR (1) KR20040101499A (pt)
CN (1) CN1649575A (pt)
AU (1) AU2003231730A1 (pt)
BR (1) BR0309747A (pt)
CA (1) CA2483275A1 (pt)
MX (1) MXPA04010132A (pt)
PL (1) PL373787A1 (pt)
WO (1) WO2003092669A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
EP1827602B1 (en) * 2004-11-26 2011-03-09 Novagali Pharma S.A. Modulating retinal pigmented epithelium permeaion by inhibiting vegfr-1
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
CN101370505B (zh) * 2005-11-29 2012-03-21 史密丝克莱恩比彻姆公司 新生血管性眼病如黄斑变性、血管样纹、葡萄膜炎和黄斑水肿的治疗
JP2012062258A (ja) * 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
TW201325601A (zh) * 2011-09-16 2013-07-01 Foresight Biotherapeutics Inc 安定之普維酮－碘組成物
KR102159164B1 (ko) * 2013-03-29 2020-09-23 에스크엣 인크. 안질환용 치료제
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
CA2381926A1 (en) * 1999-08-31 2001-03-08 Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac

Also Published As

Publication number Publication date
CA2483275A1 (en) 2003-11-13
KR20040101499A (ko) 2004-12-02
AU2003231730A1 (en) 2003-11-17
US20030207941A1 (en) 2003-11-06
EP1507522A2 (en) 2005-02-23
WO2003092669A3 (en) 2004-03-25
CN1649575A (zh) 2005-08-03
PL373787A1 (en) 2005-09-19
WO2003092669A2 (en) 2003-11-13
JP2005525408A (ja) 2005-08-25
MXPA04010132A (es) 2005-01-25
US20050143468A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
BR9909795A (pt) Derivados de epotilona 12, 13-modificados
SE0100901D0 (sv) New composition
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
DE60327745D1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
BRPI0508137A (pt) composição de tratamento dos cabelos, método de alisamento de cabelos e uso da composição
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
WO2003080582A3 (de) Fredericamycin-derivate
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
DK1307227T3 (da) Farmaceutiske sammensætninger
BR0315580A (pt) Derivados de metileno uréia
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR9807145A (pt) 2-metoxiimino-2-(piridiniloximetil) fenilacetamidas com derivados de ácido carboxìlico no anel de piridina como fungicidas.
BR0309747A (pt) Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
WO2003065991A3 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]